The drug, developed by Gilead Sciences, is administered twice a year and, given its effectiveness, is a real breakthrough in the fight against the human immunodeficiency virus.
The real name of the drug is lenacapavir, but it will be sold under the trade name Yeztugo. During clinical trials among adults and adolescents, it has demonstrated an effectiveness of more than 99.9%.
Despite the effectiveness, experts' optimism is overshadowed by the likely high cost. A similar drug, cabotegravir, which is administered every two months, costs tens of thousands of dollars a year and has not yet been widely used. It is expected that the starting price of Yeztugo in the USA can reach 25 thousand per year, although in preventive use it should be lower than 39 thousand - the current cost of the lenacapavir treatment course.
Researchers and human rights activists urge Gilead to significantly reduce the price to overcome the HIV epidemic. korrespondent.net.
